Evaluation the early effects of single high dose radioiodine therapy on lacrimal gland function

The therapeutic administration of [131]I for thyroid remnant ablation and for metastases comes up with some adverse effects. This study was conducted to investigate whether single high dose radioiodine therapy affects lacrimal gland functions or not. Seventy-eight eyes of 39 patients, who were diagnosed as differentiated thyroid carcinoma, were objectively tested with Schiermer's test and tear film break-up time test; before and 1 and 6 months after high dose [

Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas

To demonstrate long-term changes in the prevalence of several types of metabolic derangements in subjects with nonfunctioning adrenal adenomas. 273 subjects with adrenal adenomas, including 231 with nonfunctioning adenoma and 42 with subclinical Cushing's syndrome [sCS], were evaluated with respect to anthropometric and laboratory characteristics and prevalence of type 2 diabetes mellitus [T2DM], hypertension, dys-lipidemia, metabolic syndrome [MS], prediabetes and cardiovascular disease [CVD]. Median duration was 24 months. Follow-up data of 114 participants with nonfunctioning adrenal adenomas are also presented while those of 117 were missing. Follow-up data regarding changes in anthropometric and laboratory parameters and prevalence rates of metabolic disturbances were obtained from the medical records. The prevalence rates for both patients with non-functioning adenoma and sCS were: dyslipidemia: 161 [59%], hypertension: 147 [54%], MS: 128 [47%], prediabetes: 62 [23%], T2DM: 49 [18%], and CVD: 21 [8%]. Hypertension and CVD were prevalent in subjects with sCS compared to participants with nonfunctioning adenoma. In follow-up, body mass index [p = 0.005], systolic blood pressure [p < 0.001], waist circumference [p = 0.005], homeostasis model assessment [p = 0.046], high-sensitivity C-reactive protein [p =0.023], total cholesterol [p < 0.001] and low-density lipopro-tein cholesterol [p < 0.001] and prevalence of hypertension [p < 0.001], dyslipidemia [p < 0.001], prediabetes [p < 0.001] and MS [p < 0.01] significantly increased in subjects with nonfunctioning adenoma. The data showed that nonfunctioning adrenal adenomas were associated with the development or deterioration of atherosclerotic risk factors. Therefore, follow-up and management strategies should be developed to decrease atherosclerotic morbidity in those individuals

imatinib mesylate therapy cause growth hormone deficiency?

The purpose of this study was to determine whether or not imatinib mesylate therapy induces growth hormone deficiency [GHD]. Seventeen patients with chronic myloid leukemia [CML] were enrolled in the study. The glucagons stimulation test [GST], and standard deviation scores [SDSs] of insulin-like growth factor 1 [IGF-I] and insulin-like growth factor binging protein [IGFBP-3] were used to determine GHD. The L-dopa test was performed on those with IGF-I SDSs above the -1.8 cut-off level. Of the 17 patients in the study, 12 [70%] had severe GHD [serum GH level<3 micro g/l after GST]. IGF-I SDSs and IGFBP-3 SDSs were below -1.8 showed insufficient GH response to L-dopa stimulation. Nine subjects [52%] had both severe GHD based on GST response and IGF-I SDS below -1.8. If an IGF-I SDS cut-off value 1<-3 were used, 5 out of 17 subjects [30%] would be classified as GH deficient. These same patients also showed severe GHD based on GST response. The data showed that a large number of patients on imatinib mesylate therapy had GH deficiency. A study involving a larger number of patients with a matched control group is needed to confirm the present observations